Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio entered into a definitive agreement to merge with privately held Serapha Bio in an all-stock transaction, pivoting away from its failed ecDNA program BBI-940 to advance Serapha's in vivo base editing therapy SERP-01 for Alpha-1 Antitrypsin Deficiency. The transaction is backed by a $230 million concurrent private placement co-led by RA Capital and RTW Investments; BOLD stockholders will receive a special cash dividend of approximately $44 to $48 million but will retain only about 3.7% ownership of the combined company.
Key figures
- Series a funded
- $138 million
- Cash dividend range
- $44 to $48 million
- Private placement amount
- $230 million
- Additional funding expected
- $92 million
- Yoltech milestone potential
- over $2 billion
- Former bold ownership percent
- 3.7%
- Former serapha ownership percent
- 96.3%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.